Melanoma/Skin Cancer News

Acral lentiginous melanoma survival is less likely in patients from lower socioeconomic groups, as well as in Black or Hispanic white patients, according to a study.

Cancer clinical trials supporting FDA approvals significantly differ in reporting of withdrawal of consent or loss to follow-up and early drug discontinuation for adverse events, according to study results.

American Association for Cancer Research released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and research practice.

Cancer cell-derived or allergic reaction-released histamine dampened antitumor immunity and conferred resistance to cancer immunotherapy, according to a retrospective study published in Cancer Cell.

Patients with cancer had few differences in reported adverse events compared with people without cancer after receiving COVID-19 vaccines, according to study results published in JNCCN — Journal of the National Comprehensive Cancer Network.

Older patients with cancer benefited from single-agent immune checkpoint inhibitors but had higher rates of adverse events and therapy discontinuation with increasing age, according to results of a retrospective study in JAMA Oncology.

Germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types, according to study results.

Melanoma thickness has a progressive relationship with decreasing survival, however that relationship is lost in patients with melanomas 15 mm or thicker, according to a study.

President Joe Biden has unfinished business with cancer.

Residents of rural areas demonstrated higher levels of cancer fatalism and cancer information overload than urban residents, according to a study in Cancer Epidemiology, Biomarkers & Prevention.